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Abstract
Background The treatment of muscle wasting is accompanied by benefits in other organs, possibly resulting from muscle–
organ crosstalk. However, how the muscle communicates with these organs is less understood. Two microRNAs (miRs),
miR-23a and miR-27a, are located together in a gene cluster and regulate proteins that are involved in the atrophy process.
MiR-23a/27a has been shown to reduce muscle wasting and act as an anti-fibrotic agent. We hypothesized that intramus-
cular injection of miR-23a/27a would counteract both muscle wasting and renal fibrosis lesions in a streptozotocin-induced
diabetic model.
Methods We generated an adeno-associated virus (AAV) that overexpresses the miR-23a∼27a∼24-2 precursor RNA and
injected it into the tibialis anterior muscle of streptozotocin-induced diabetic mice. Muscle cross-section area
(immunohistology plus software measurement) and muscle function (grip strength) were used to evaluate muscle atrophy.
Fibrosis-related proteins were measured by western blot to monitor renal damage. In some cases, AAV-GFP was used to mimic
the miR movement in vivo, allowing us to track organ redistribution by using the Xtreme Imaging System.
Results The injection of AAV-miR-23a/27a increased the levels of miR-23a and miR-27a as well as increased phosphorylated
Akt, attenuated the levels of FoxO1 and PTEN proteins, and reduced the abundance of TRIM63/MuRF1 and FBXO32/atrogin-1
in skeletal muscles. It also decreased myostatin mRNA and protein levels as well as the levels of phosphorylated pSMAD2/3.
Provision of miR-23a/27a attenuates the diabetes-induced reduction of muscle cross-sectional area and muscle function. Cu-
riously, the serum BUN of diabetic animals was reduced in mice undergoing the miR-23a/27a intervention. Renal fibrosis, eval-
uated by Masson trichromatic staining, was also decreased as were kidney levels of phosphorylated SMAD2/3, alpha smooth
muscle actin, fibronectin, and collagen. In diabetic mice injected intramuscularly with AAV-GFP, GFP fluorescence levels in the
kidneys showed linear correlation with the levels in injected muscle when examined by linear regression. Following intramus-
cular injection of AAV-miR-23a∼27a∼24-2, the levels of miR-23a and miR-27a in serum exosomes and kidney were significantly
increased compared with samples from control virus-injected mice; however, no viral DNA was detected in the kidney.
Conclusions We conclude that overexpression of miR-23a/27a in muscle prevents diabetes-induced muscle cachexia and at-
tenuates renal fibrosis lesions via muscle–kidney crosstalk. Further, this crosstalk involves movement of miR potentially
through muscle originated exosomes and serum distribution without movement of AAV. These results could provide new ap-
proaches for developing therapeutic strategies for diabetic nephropathy with muscle wasting.
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Introduction
Muscle wasting is an independent index for mortality and
morbidity in almost every chronic kidney disease (CKD) pa-
tient.1–3 It is also an acknowledged risk factor in other types
of catabolic conditions, such as diabetes, heart failure, and
cancer.4–6 Diabetes is the leading cause of CKD, which is
responsible for about 30% of all end-stage renal disease
cases in the United States and other Western societies.7,8 Al-
though therapeutic approaches to glycaemic control and
recently developed renoprotective drugs are partially effec-
tive against the symptoms of diabetic nephropathy, this
disorder is still a major cause of increased mortality in dia-
betic patients.7
Earlier, we found that insulin deficiency and insulin resis-
tance lead to the down-regulation of the insulin and IGF-1
signalling pathways that are critical for induction of muscle
wasting in catabolic disease.9,10 Akt, also known as protein ki-
nase B, is a serine/threonine-specific protein kinase that plays
a central role in regulating muscle mass. In general, up-
regulation of the IGF-1/insulin/Akt pathway increases protein
synthesis, decreases protein degradation, and, therefore, an-
tagonizes muscle wasting.
Myostatin (also known as growth differentiation factor 8)
is a negative regulator of muscle mass. It is an important
member of the transforming growth factor-β (TGF-β) super-
family that regulates cell proliferation, differentiation, and
death.11 The Small body size and Mothers Against
Decapentaplegic Homologue 2 and 3 (SMAD2 and SMAD3)
proteins are transcription factors that are phosphorylated in
response to TGF-β and myostatin; they up-regulate the ex-
pression of various fibrosis-related genes.12 In CKD, increased
TGF-β in kidney leads to activation of SMAD2/3, which causes
proliferation of myofibroblast, accumulation of extracellular
matrix proteins, and eventually kidney fibrosis. In skeletal
muscle, activation of SMAD2/3 by myostatin inhibits myo-
blast differentiation into mature muscle fibres.13 In contrast,
pharmacological inhibition of myostatin markedly enhances
satellite cell function as well as decreases the rate of protein
degradation and increases protein synthesis in skeletal
muscles.14
MicroRNAs (miRs) have emerged as key regulators of meta-
bolic homoeostasis, suggesting that they may provide
effective treatment for diabetes mellitus and its complica-
tions.15,16 These small non-coding RNAs target important
pathway components for insulin signalling,TGF/myostatin cas-
cade, and inflammation.17 Earlier, we found 22 miRs which are
altered in a muscle atrophy model of CKD mouse, including a
decrease in miR-23a.15 miR-23a is located in a cluster with
miR-27a and miR-24-2 (miR-23a∼27a∼24-2) on chromosome
8 (chromosome 19 in human). The precursor miR is processed
into individual miRs-miR-23a, miR-27a, and miR-24-2—which
target different sets of mRNAs. We recently reported that ex-
pression of miR-23a/27amimics resistance exercise to prevent
CKD-induced muscle atrophy by altering the abundance of
multiple proteins.18 In addition, we showed that miR-23a
was decreased in the skeletal muscle of diabetic rats consis-
tent with the muscle atrophy seen during diabetes mellitus.19
Other groups have reported that ectopic expression of miR-
23a protects against dexamethasone-induced skeletal muscle
atrophy in part by targeting the 30-UTR of atrophy-inducing
two E3 ubiquitin ligases, TRIM63/MuRF1, and
FBXO32/atrogin-1.20
In this study, we explore the possibility that exosomes,
small (30-120 nm) extracellular vesicles, facilitate the
crosstalk between muscle and kidney. We began by testing
the hypothesis that overexpression of miR-23a/27a in
skeletal muscle of STZ-induced diabetic mice would lead to
attenuation of muscle loss. During the course of our experi-
ments, we found less fibrosis lesions in the kidneys of
diabetic mice overexpressing miR-23a/27a in skeletal muscle.
This led us to test whether miR-23a/27a-containing exosome
released from skeletal muscle could affect the fibrotic pro-
cess in the kidney by down-regulating the TGFβ/SMAD
cascade. Finally, we used adeno-associated virus (AAV)-green
fluorescent protein (GFP) to test whether miR-23a~27a~24-2
expressed in skeletal muscle could be transported by circulat-
ing exosomes to kidney.
Methods
Animals and diabetic mice model
The mice (C57BL/6J) were purchased from Jackson Laborato-
ries (Bar Harbour, ME, USA) and bred in the Department of
Animal Resources at Emory University.21 Diabetic mice were
produced by STZ (Pfanstiehl Lab, Waukegan IL, USA) injection
by using a 2-day protocol in which 150 mg/kg (prepared fresh
in 0.1 M citrate buffer, pH 4.0) was given by intra-peritoneal
injection for 2 consecutive days. The control mice were
injected with vehicle only. The experiments are performed
in male mice because, in our hands, female mice resist diabe-
tes after injection of STZ. Mice (C57BL/6J, 6–8 weeks) were
randomly assigned into four groups: control/AAV-GFP (con-
trol), control/AAV-miR-23a∼27a∼24-2, diabetes/AAV-GFP,
and diabetes/AAV-miR-23a∼27a∼24-2 (n = 12/group). The
muscle and kidney were harvested 12 weeks after the second
STZ injection (Table 1). Muscle grip function was measured by
using a mouse grip strength metre with dual computerized
sensors to detect and record the grip force (Columbus Instru-
ments, Columbus, OH).22 The technicians were blinded to the
grip-strength measurements. Blood urea nitrogen (BUN)
was measured with a BUN Kinetic Procedure Kit (Thermo
Electron, Louisville, CO). Serum creatinine was measured with
a Serum Creatinine detection kit (KBO2-H1; Arbor Assays,
Ann Arbor, MI).
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Production of high titre adeno-associated virus
The miR-23a~27a~24-2 was cloned into cis-plasmid pTR-UF5
vector (pTR-miR-23a~27a~24-2) with CMV promoter by
Emory Integrated Genomics Core. Two controls were pre-
pared. The miR-mimic control and GFP gene were each
cloned into the pTR-UF5 vector to produce the two AAV-
controls. Cells transfected with either control showed the
same miR expression, so to facilitate tracking, we used
AAV-GFP for the experiment control virus. The AAV was pro-
duced and tittered by the Viral Vector Core of the Emory by
using three plasmid system: pTR-miR-23a~27a~24-2 or pTR-
GFP, pAAV2/9 (p5E18-VD2/9, AAV trans-plasmid containing
AAV rep and cap genes), and pDF6 (adenovirus helper plas-
mid). The stock virus titres for AAV-miR-23 were 3.4 × 1014
and 6.5 × 1014 for AAV-control. Fifteen microlitres of viral
preparation (1010) was injected into TA muscle over 5 min
by using a Hamilton syringe with 30 gauge needle.21 Only
left legs of the mouse were injected with recombinant
AAV (rAAV).
Western blot and antibodies
Equal amounts of protein from TA muscle or whole kidney
were used for western blot.23,24 Protein bands were scanned
and quantified by using the Li-cor Odyssey infrared scanning
system (Li-COR Biosciences, Lincoin, Nebraska). Primary anti-
bodies are listed in supporting information.
Exosome isolation, NanoSight measurement, and
in vivo imaging
Serum was 5× diluted with phosphate-buffered saline (PBS)
and cell debris, and organelles were eliminated by centrifuga-
tion at 1000g for 10 min, 4 °C. The supernatant fraction was
further centrifuged at 16 000g for 30 min. The second super-
natant was sterile filtered through a 0.22-μm filter. Exosomes
were pelleted at 120 000g for 90 min at 4 °C (L8-70 M ultra-
centrifuge, Beckman-Coulter, Indianapolis IN). Finally, the
exosome pellets were re-suspended in 100 to 400-μL PBS.
Protein content was quantitated by using a Bradford protein
assay. Exosome concentration and size (Figure S3) were
measured with NanoSight instruments, which performs nano-
particle tracking analysis (NanoSight NS300, Malvern Instru-
ments, Inc. Westborough, MA). In vivo exosome distribution
imaged was taken with the Bruker Small Animal Optical Imag-
ing System (In-Vivo Xtreme II; Billerica, MA).
Quantitative PCR
Total RNAs from muscle and kidney were extracted by using
Tri-Reagent (Molecular Research Inc., Cincinnati, OH).
Exosomal RNA was isolated by using miRNAeasy kit
(217004, Qiagen Sciences, Germantown, MD) and quantified
by using a NanoDrop spectrophotometer (Thermo Scientific,
Wilmington, DE). For mRNA expression, total RNA (1–2 μg)
was reverse transcribed by using a Thermoscript RT-PCR kit
(Invitrogen Carlsbad, CA). Real-time quantitative PCR (qPCR)
was performed with the SYBR Green PCR reagent (Bio-Rad,
Hercules, CA) and the following PCR parameters: 94 °C for
2 min and 40 cycles at 94 °C for 15 s, 55 °C for 30 s, and
72 °C for 30 s with final extension at 72 °C for 10 min.22,25
The Cq (threshold cycle) was defined as the number of cycles
required for the fluorescence signal to exceed the detection
threshold. Individual mRNA expression was standardized to
18S gene, and expression was calculated as the difference be-
tween the threshold values of the two genes (ΔΔcq). Melting
curve analysis was always performed during real-time qPCR
to analyse and verify the specificity of the reaction. Primers
for mRNA are listed in Table 2. For miR, RNA was reverse
transcribed by using a universal cDNA synthesis kit II (Exiqon
203301, Wobum, MA); the primers were purchased from
Exiqon. Real-time qPCR was performed with the ExiLENT
SYBR green master mix (Exiqon 203421). Expressions of indi-
vidual miR-23a-3p, miR-27a-3p, and miR-24-3p were stan-
dardized to the mouse U6 mRNA and calculated as the
difference between the threshold values of the two genes
(ΔΔcq). The expression of individual miRs in serum exosomes
was normalized to miR-103a.
Table 1 Muscle and body weight
Control + miR-ctrl Control + miR-23/27 Diabetes + miR-ctrl Diabetes + miR-23/27
Body weight (g) 22.7 ± 1.1 21.6 ± 1.9 19.6 ± 1.5# 20.7 ± 1.1*#
aTA (mg) 45.9 ± 3.9 47.5 ± 5.1 36.1 ± 6.1# 43.5 ± 2.9*
Soleus (mg) 8.9 ± 0.9 9.5 ± 0.6 6.2 ± 0.5# 7.9 ± 0.9*#
bEDL (mg) 9.5 ± 0.9 9.9 ± 0.8 7.1 ± 0.4# 8.5 ± 0.9*#
Gastrocnemius (mg) 123 ± 12.2 125 ± 10.1 88 ± 11.1# 112 ± 10.4*
Glucose (mg/dL) 99.5 ± 4.8 106 ± 5.4 306 ± 19.1# 276 ± 9.9#
All data are presented as mean ± s.e.; n = 9.
aTA, tibialis anterior.
bEDL, extensor digitorum longus.
#p < 0.05 vs. control.
*p < 0.05 vs. diabetes.
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Muscle and kidney histology
Tissues were fixed in 3.7% formaldehyde/PBS (pH 7.4) and
dehydration, paraffinization, and section at Histology Lab of
Department of Medicine. Masson Trichromatic staining was
performed with a Masson modified IMEB stain kit (K7298,
IMEB inc. San Marcos, CA). Images were visualized with an
Olympus 1× 51 inverted microscopes and captured by
DP73-1-51-17MP colour camera. Collagen area (blue colour)
in kidney was measured by using the CellSens Dimension
1.9 with count and measure full Software (Olympus, Melville,
NY, USA) and calculated from 10 individual fields.
For immunohistology: muscles were embedded in Tissue
Freezing Media (TBS; Fisher, Pittsburgh, PA, USA) in
isopentane cooled in dry ice. Cross sections (10 mm) from
the midbelly of different muscles mounted on gelatin-coated
slides were fixed in 4% paraformaldehyde for 10 min. Tissue
was permeabilized in 0.05% Triton X-100 (in PBS) for 10 min
and quench-fixed in 50-mM NH4Cl for another 10 min. Sam-
ples were blocked with 5% bovine serum albumin for 1 h,
followed by incubation overnight with primary antibody. Sec-
tions were subsequently washed and incubated for 60 min
with FITC-labelled anti-rabbit IgG (111-095-144; diluted
1:100; Jackson Immuno Research Lab, West Grove, PA). Nu-
clei were stained by DAPI. Images were visualized with an
Olympus 1X51 inverted fluorescence microscope and cap-
tured by DP73-1-51-17MP colour camera. Muscle fibre
cross-sectional area was determined in TA muscles by using
an anti-laminin antibody (1:50 dilution; Sigma-Aldrich), and
at least 500 individual myofibres per muscle were measured.
Primary muscle satellite cell culture
Satellite cells were isolated from the hind limb muscles of 4-
month-old mice. A Skeletal Muscle Dissociation Kit (130-098-
305; MACS, Miltenyi Biotec, Inc. Auburn, CA) was used to dis-
sociate mouse skeletal muscle tissue into cell suspensions,
and a Satellite Cell Isolation Kit (130-104-267, MACS) was
used to isolate satellite cells. Isolated satellite cells were pas-
saged a maximum of 5 times. Cells were cultured in Ham’s F-
10 Nutrient Mixture medium (Invitrogen) with 20% fetal bo-
vine serum, 100-u/mL penicillin, and 100-μg/mL streptomy-
cin (growth medium). Myotube differentiation was inhibited
by the addition of 5-ng/ml human β-fibroblast growth factor
(Atlanta Biologicals, Atlanta, GA) to the media. Fibroblast
growth factor was removed for 2 days before the
experiments. Immunohistochemistry was used to assess the
cell purity. Satellites were stained with anti-eMyHC or anti-
α-smooth muscle actin (Sigma) to identify purification and
contaminating fibroblasts which were minimal.18
Luciferase reporter assay and transfection26
Effectene transfection reagent was used for transfection
(Qiagen, Valencia, CA). Firefly and Renilla luciferase activities
were measured by dual-luciferase assays (Promega) by using
TD-20/20 Luminometer (Turner designs, Sunnyvale, CA). The
luciferase report vectors (pMIR-REPORT Luciferase) were pur-
chased from Applied BIOSYSTEMS (Waltham, MA), and con-
structs were made by Emory Integrated Genomics Core.
miR-23a/27a mimic (RIDIAN mmu-miR-23a/27aa-3p) and
miR-23a/27a inhibitor (sh-miR-23a/27a, RIDIAN mmu-miR-
23a/27ab-3p-hairpin inhibitor) were purchased from GE
Healthcare Dharmacon Inc (Chicago, IL).
Statistical analysis
Data were presented as mean ± SEM. To identify significant
differences between two groups, comparisons were made
by using the paired t-test. When multiple treatments were
compared, ANOVA was performed with a post-hoc analysis
by the Student–Newman–Keuls test. The relationship be-
tween muscle and kidney GFP intensity was calculated by lin-
ear regression modelling. Differences with p values <0.05
were considered significant.
Table 2 Primer sequences
Name Sequence Amplicon Code
FBXO32/Atrogen-1 Forward GCAGAGAGTCGGCAAGTC 142 NM_026346
Reverse CAG GTC GGT GAT CGT GAG
TRIM63/MuRF-1 Forward AGTGTCCATGTCTGGAGGTCGTTT 139 DQ229108
Reverse ACTGGAGCACTCCTGCTTGTAGAT
Myostatin Forward GACAGTGTCAGCGTGTGGGTT 74 NM_001112698
Reverse CCAACACCATCACCTCCTT
AAV-ITR Forward CGAGGTGACAGAGACCACAA 280 X93167.1
Reverse CTGGAGTCAAGCCAGACACA
18S Forward CCA GAG CGA AAG CAT TTG CCA AGA 101 X00686
Reverse TCG GCA TCG TTT ATG GTC GGA ACT
GAPDH Forward CACCATCTTCCAGGAGCGAG 101 NM-008084
Reverse CCTTCTCCATGGTGGTGAAGAC
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diabetic-induced loss of muscle mass
To overexpress miR-23a and miR-27a, a rAAV that encodes
the miR-23a~27a~24-2 precursor miR (AAV-miR-
23a~27a~24-2) was developed; an AAV encoding GFP (AAV-
GFP) was used as a control virus. AAV-miR-23a~27a~24-2
(1010 virus genomes) was injected into the left tibialis ante-
rior (TA) muscle of control mice and mice with STZ-induced
diabetes. Diabetic mice had a blood glucose level that was
3 times higher than the value for control mice (Table 1). Visu-
alization of GFP in the TA muscle of control mice was used to
confirm that muscle injection with AAV was successful
(Figure 1A). The amount of GFP protein was significantly in-
creased 1 week after AAV-GFP injection (Figure 1B). In mice
injected with rAAV-miR-23a~27a~24-2, the expression of
miR-23a-3p was increased 7.3-fold in the muscle of control
mice and 4.6-fold in diabetic mice after rAAV transduction
(Figure 1C). The expression of miR-27a also increased in TA
muscle transduced with rAAV-miR-23a~27a~24-2 of both
control and diabetic mice. As seen in our earlier study,18
there was no statistical difference in the level of miR-24-2
in TA muscle of mice injected with AAV-miR-23a∼27a∼24-2.
The intervention of AAV-miR-23a∼27a∼24-2 in TA muscle
ameliorated the diabetes-induced decrease of muscle
weights (Table 1). Interestingly, in un-injected muscle, the
muscle weights of soleus muscle (slow-twitch, red fibre), ex-
tensor digitorum longus muscle (fast-twitch, white fibre),
and gastrocnemius muscles were also significantly improved
by injection of AAV-miR-23a∼27a∼24-2 in TA muscles of
diabetic mice vs. control mice. Grip strength, a broad
measurement of muscle function, was decreased in the
diabetic mice cohort relative to controls; provision of AAV-
miR-23a∼27a∼24-2 to diabetic mice increased their muscle
grip capacity compared with AAV-GFP treated diabetic mice
(Figure 1D). These data indicate that exogenous miR-23a/
27a attenuates diabetes-induced muscle mass loss and
improves muscle function.
Exogenous miR-23a/27a prevents muscle atrophy
and improves protein anabolic signalling
To investigate whether increasing miR-23a/27a in muscle
ameliorates diabetes-induced reduction in muscle fibre size,
the cross-sectional area (CSA) of muscle fibres was measured
in frozen sections of TA muscles. Differences in the overall
size distribution of muscle fibres from control, diabetic, and
diabetic AAV-23a∼27a∼24-2-injected muscles are shown in
Figure 2A. There is no statistical difference of the muscle
CSAs between control plus AAV-ctrl (3190 ± 153 μm2) and
control plus AAV-miR-23a/27a (3210 ± 146 μm2)-treated
mice. Statistical analysis of the muscle fibre CSA distribution
data from the three cohorts indicates that diabetes reduces
the CSA of muscle fibres and provision of miR-23a∼27a∼24-
2 attenuates that reduction.
We also examined proteins that are related to IGF-1 signal-
ling pathway because of their roles in regulating muscle pro-
tein turnover. Diabetes decreased Akt phosphorylation
(pAkt), whereas PTEN, an antagonist of Akt activation and
negative regulator of muscle mass, was increased 1.8-fold in
diabetic muscle compared with controls. Consistent with
these findings, the level of phosphorylated FoxO1 was de-
creased in diabetic mice (Figure 2B). Two FoxO1
transcriptional-regulated proteins, TRIM63/MuRF1 and
FBXO32/atrogin-1, were significantly increased. All of these
responses were attenuated in the muscles of diabetic mice
injected with AAV-miR-23a∼27a∼24-2 (Figure 2B). Diabetes
also increases the production a 14-kDa peptide of actin that
is cleaved by activated caspase-3; this peptide fragment
serves as a marker for myofibrillar protein degradation in cat-
abolic diseases.21,27,28 Consistently with our earlier reports,
diabetes increased the amount of this 14-kDa actin
fragment three-fold compared with normal mice, and rAAV-
miR-23a∼27a∼24-2 reduced the appearance of the actin
fragment (Figure 2C). Because fibrosis can lead to a reduction
in muscle strength, we also tested for evidence of muscle
fibrosis by Masson’s trichrome staining of muscle cross
sections. No significant collagen deposition was seen in dia-
betic muscle, regardless of whether they were injected with
AAV-miR-23a∼27a∼24-2 or not (Figure S1). These results sug-
gest that exogenous miR-23a/27a-mediated up-regulation of
Akt phosphorylation, inhibition of E3 ubiquitin ligases, and at-
tenuation of the diabetes-induced myofibrillar protein degra-
dation contribute to the improvement in muscle proteostasis.
Exogenous miR-23a/27a suppresses myostatin
signalling
Increased expression of myostatin is often associated with
loss of muscle mass in chronic wasting conditions (e.g.,
diabetes or CKD).14,29 As expected, the mRNA expression of
myostatin, TRIM63/MuRF1, and FBXO32/atrogin-1 mRNA
were increased in the muscle of diabetic mice (Figure 3
A). Similarly, the protein abundance of myostatin, phosphor-
ylation of SMAD2/3, and signalling proteins downstream of
myostatin were also increased (Figure 3B). Ectopic expression
of the miR-23a∼27a∼24-2 precursor significantly suppresses
the increase in both myostatin mRNA and protein in diabetic
mice (Figure 3A and B). Provision of the miR-23a/27a
precursor normalized the amounts of phosphorylated
SMAD2/3 in diabetic muscle.
While analysing the SMAD2/3 data, we noted that both
the phosphorylation and amount of SMAD3 protein were
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Figure 1 Recombinant adeno-associated virus (AAV)-23a~27a~24-2 increased the microRNA (miR)-23a/27a expression in the muscle of diabetic mice.
(A) Shown are representative frozen cross sections from tibialis anterior (TA) muscles transduced with AAV in normal control mice. (right column) Fluo-
rescence microscopy images to detect green fluorescent protein (GFP) expression; (left column) bright-field microscopic imagines of muscle cross sec-
tion. (top row) Microscopy images in mice with AAV-Empty (no insert in AAV expression vector) transduction. (bottom row) Microscopy images in mice
with AAV-GFP transduction. (B) The time course of GFP protein abundance was measured by western blotting in TA muscle lysates from normal mice
after AAV-GFP transduction. (C) Total RNA was extracted from TA muscle of control plus AAV-GFP (AAV-ctrl), control plus AAV-miR-23a/27a, diabetes
(DM) plus AAV-ctrl, and DM plus AAV-miR-23a/27a mice. The expressions of miR-23a-3p, miR-27a-3p, and miR-24-2 were assayed by real-time quan-
titative polymerase chain reaction. The bar graph shows miR from the TA muscle of each group of mice compared with levels in control mice + AAV-ctrl
(represented by a line at one-fold). Results are normalized to U6 (bars: mean ± s.e.; n = 9/group;
*
p < 0.05 vs. diabetes and
#
p < 0.05 vs. control). (D)
Hind limb muscle function in each group of mice was assessed by the grip strength. The bar graph shows grip strength from each group of mice com-
pared with levels in control mice (represented as a dashed line at one-fold). KGF2 = kilogram force/100; bars: mean ± s.e.; n = 9/group; *p < 0.05 vs.
diabetes and #p < 0.05 vs. control.
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Figure 2 Exogenous microRNA (miR)-23a/27a improved muscle metabolic-related proteins and attenuated diabetes-induced actin breakdown. (A) A
representative CSA of tibialis anterior (TA) muscle of control plus adeno-associated virus (AAV)-green fluorescent protein (AAV-ctrl), control plus
AAV-miR-23a/27a, diabetes (DM) plus AAV-ctrl, and DM plus AAV-miR-23a/27a mice are compared. Cryosections of TA muscles were immunostained
with anti-laminin antibody. The average of cross-section area is shown at the bottom of images. The frequency distribution of fibre CSA in control (grey
bar), diabetes (open bar), and diabetes plus miR-23a/27a (black bar) mice is presented as per cent cross-section area of fibres. Data: mean ± s.e.; n = 9/
group;
*
p < 0.05 vs. diabetes and
#
p < 0.05 vs. control. (B) The metabolic-related proteins Akt, p-Akt, PTEN, FoxO1, pFoxO1, TRIM63/MuRF1, and
FBXO32/atrogin-1 were measured by western blotting in different groups of mice. The bar graph shows the fold change of the each protein band
or ratio (phospho-protein to total protein) compared with levels in control mice (represented by a line at one-fold). Results are normalized to glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH; bars: mean ± s.e.; n = 9/group;
*
p < 0.05 vs. diabetes and
#
p < 0.05 vs. control). (C) The myofibrillar
protein breakdown was measured by actin cleavage by using western blotting in different groups of mice. Cleaved actin (14 kDa) was detected by an
antibody against the c-terminal 11 amino acids of actin. The bar graph shows the fold change of the 14-kDa actin band compared with levels in control
mice (represented by a line at one-fold). Results are normalized to GAPDH (bars: mean ± s.e.; n = 12/group; *p < 0.05 vs. diabetes and #p < 0.05 vs.
control).
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Figure 3 Exogenous microRNA (miR)-23a/27a repressed myostatin miR and protein. (A) Total RNA was extracted from tibialis anterior (TA) muscle of
control plus adeno-associated virus (AAV)-green fluorescent protein (AAV-ctrl), control plus AAV-miR-23a/27a, diabetes (DM) plus AAV-ctrl, and DM
plus AAV-miR-23a/27a mice. The expressions of myostatin, TRIM63/MuRF1, and FBXO32/atrogin-1 were assayed by real-time quantitative polymerase
chain reaction. The bar graph shows myostatin expression from the TA muscle of each group of mice compared with levels in control mice (repre-
sented by a line at one-fold). Results are normalized to 18S (bars: mean ± s.e.; n = 9/group; *p < 0.05 vs. diabetes and #p < 0.05 vs. control). (B)
Myostatin, SMAD 2/3, and phosphorylated SMAD 2/3 (pSer465 or pSer223 SMAD2/3) were measured by western blotting in TA muscle lysates from
different group mice. The bar graph shows total myostatin (left group) or the ratios of each phospho-SMAD to total SMAD protein. The fold change of
the each protein band or ratio is compared with levels in control mice (represented by a line at one-fold). All band densities were normalized to density
of glyceraldehyde 3-phosphate dehydrogenase (bars: mean ± s.e.; n = 9/group;
*
p < 0.05 vs. control and
#
p < 0.05 vs. chronic kidney disease). (C) miR-
23a/27a binding on 30-UTR of SMAD-3 and inhibition of SMAD3 translation. Muscle progenitor cells (myotubes) were transfected with pLuc-ctrl, pMIR-
SMAD3/1227–1303 (SMAD) with miR-23-mimic (miR-23) or miR-23-inhibitor (sh-miR-23). Luciferase activity in myotubes that received the pLuc-ctrl
with control mimic was designated as the 100% (presented by a horizontal line in the graph). The other bars show the response of the myotubes
to miR-23 or sh-miR-23 expressed as a per cent of the control. Triplicate determinations were made in each condition, and each experiment was re-
peated a total of three times; the firefly luciferase results were normalized by renilla luciferase activity. Data: mean ± s.e. (n = 9;
#
p < 0.05 vs. mimic-
ctrl).
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increased by diabetes (Figure 3B). An in silico analysis of the
30-UTR of SMAD3 predicted a highly conserved binding site
for miR-23a. To experimentally confirm that miR-23a inter-
acts with the SMAD3 mRNA, the miR-23a SMAD3 target site
(1267 to 1273 nt) was cloned into a 30-UTR luciferase reporter
construct (pLUC-SMAD3) and transfected into muscle satel-
lite cells. When transfected cells were incubated with a
mouse miR-23a mimetic (mmu-miR-23a), luciferase activity
was decreased, and the response was blocked by mutating
the miR-23a binding site. Incubation of transfected cells with
an miR-23a inhibitor (mmu-miR-23a–hairpin inhibitor) pro-
duced an increase in luciferase activity (Figure 3C). These
results are consistent with the observed decrease in
SMAD3 protein abundance in muscle injected with AAV-
miR-23a∼27a∼24-2 (Figure 3B) and suggest that miR-23a
overexpressed by the virus ameliorates diabetes-induced
muscle atrophy, in part, by suppressing myostatin and
SMAD3 expression.
Overexpression of miR-23a/27a in muscle
attenuates renal fibrosis lesions
In both patients and experimental animals, renal fibrosis
lesion is a consequence of diabetes.30,31 During the study, we
noted that the BUN of diabetic mice was increased, indicating
that they had renal damage. Curiously, the BUN of diabetic
mice following intramuscular injection of AAV-miR-23a-
27a∼24-2 was significantly reduced (Figure 4A, left). In dia-
betic mice, serum creatinine was also decreased in
overexpressing miR-23-27 mice compared with control AAV
treatment (Figure 4A, right). Consistent with the elevated
BUN, Masson’s trichrome staining of kidney paraffin sections
of diabetic mice revealed that collagen deposition was in-
creased (Figure 4B). This was accompanied by elevated
amounts of αSMA, fibronectin, vimentin, collagen4α1, and
collagen1α1 (Figure 4C), as well as TGF-β, total, and phosphor-
ylation of SMAD2 and SMAD3 (pSMAD2 and pSMAD3)
(Figure 4D). Moreover, the increases in collagen staining and
fibrosis-related proteins were significantly attenuated in
diabetic mice receiving the intramuscular injection of AVV-
miR-23a∼27a∼24-2, relative to untreated diabetic mice
(Figure 4B and C). Both total SMAD3 levels and phosphoryla-
tion of SMAD3were reduced in diabetic mice provisioned with
miR-23a/27a. Exogenous miR-23a/27a also decreased the ra-
tio of pSMAD2/3 to total SMAD2/3 (Figure 4D). These findings
suggest that overexpression of miR-23a/27a in muscle some-
how ameliorates kidney fibrosis lesions in diabetic mice.
Evidence of muscle–kidney cross talk
Transfer of miRNA or siRNA between cells has been reported
to occur via exosomes.32 Exosomes stabilize small RNAs and
facilitate their intercellular transfer to neighbouring muscle
and other organs.33 To investigate the possibility that miRs
(e.g. miR-23a/27a) are processed, packaged into exosomes,
and released from transduced skeletal muscle, we evaluated
serum exosomes in control and diabetic mice with or without
muscle injection of rAAV-miR-23a∼27a∼24-2. The size of
exosomes was confirmed by using NanoSight (NS300,
Malvern Instruments, Inc. Westborough, MA) measurement
(Figure S3). The expression of miR-23a and miR-27a, but
not miR-24-2, in RNA isolated from serum exosomes was in-
creased in both control and diabetic mice with muscular in-
jection of rAAV-miR-23a∼27a∼24-2 (Figure 5A). Consistent
with a crosstalk model, the levels of mature miR-23a and
miR-27a were also increased in the kidneys (Figure 5B). To
test whether muscle-derived exosomes are taken up by renal
cells, we injected AAV-GFP into the TA muscle of normal
mice. After 2 weeks, GFP fluorescence was evaluated in the
kidney, muscle, and other organs. The GFP intensity was
sharply increased in both kidneys and was also visible in the
non-injected muscle, heart, liver, and lung (Figure 6A). The in-
crease in the fluorescence intensity in kidney correlated with
an increase GFP signal in the injected TA muscle (Figure 6B).
This relationship was analysed by linear regression, and a sig-
nificant correlation was found (r = 0.596; p < 0.001). In addi-
tion, the amount of GFP protein was increased in TA muscle,
serum exosomes, and kidney in a time-dependent manner af-
ter AAV-GFP injection (Figure 6C). Fluorescence microscopy
of frozen kidney sections suggested that the increase in GFP
was predominantly localized to the interstitium, with little
fluorescence specifically localized to glomeruli (Figure S2).
To test whether the appearance of GFP or overexpression
of miR-23a/27a in kidney was simply due to viral escape from
the injected muscle, the presence of virus inverted terminal
repeat (ITR) sequences was measured in muscle, isolated se-
rum exosome, and kidney 1 week after intramuscular injec-
tion of AAV-GFP. ITR sequences were significantly increased
in the muscle of AAV transduced mice but were not changed
in DNA isolated from exosomes and kidney (Figure 6D). These
results suggest that miR-23a/27a produced in muscle could
be delivered via exosome to the kidney, where they influence
the fibrosis process.
Discussion
This study provides evidence that exogenous miR-23a/27a
can attenuate diabetes-induced muscle loss and improve
muscle function by up-regulating the insulin signalling path-
way and inhibiting the myostatin cascade. We also found that
muscle-derived miR-23a/27a can reduce kidney fibrosis as il-
lustrated by lower levels of extracellular matrix protein ex-
pression and that the mechanism includes down-regulation
of SMAD3. These results support a rationale for developing
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Figure 4 Exogenous microRNA (miR)-23a/27a ameliorated kidney fibrosis. (A) Blood urea nitrogen (BUN) and serum creatinine were measured at dif-
ferent time periods by using BUN kinetic procedure kit or serum creatinine detection kit in serum of control plus adeno-associated virus (AAV)-green
fluorescent protein (AAV-ctrl), control plus AAV-miR-23a/27a, diabetes (DM) plus AAV-ctrl, and DM plus AAV-miR-23a/27a mice. The bar graph shows
the BUN (left) and creatinine (right) levels in each group compared with levels in control mice (represented by a line at one-fold) (bars: mean ± s.e.;
n = 6/group; *p < 0.05 vs. diabetes and #p < 0.05 vs. control). (B) Shown are representative Masson’s trichrome staining of paraffin-sections from
kidneys of different groups of mice. The bar graph shows collagen amount (blue colour) measured by the CellSens Dimension 1.9 software. Results
show the fold change compared with control levels defined as one-fold (bars: mean ± s.e.; n = 6/group; *p < 0.05 vs. control). (C) The fibrosis-related
protein αSMA, fibronectin, vimentin, collagen 1α1, and collagen 4α1 were measured by western blotting in kidney lysates from different groups of
mice. The bar graph shows the fold change of the each protein band compared with levels in control mice (represented by a line at one-fold) (bars:
mean ± s.e.; n = 9/group; *p < 0.05 vs. diabetes and #p < 0.05 vs. control). (D) The protein fibrosis-related protein TGFβ, SMAD2/3, and phospho-
SMAD2/3 were measured by western blotting in kidney lysates from different group mice. The bar graph shows the fold change of the each protein
band compared with levels in control mice (represented by a line at one-fold) (bars: mean ± s.e.; n = 9/group; *p < 0.05 vs. diabetes and #p < 0.05 vs.
control).
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new strategies to simultaneously treat multiple complications
of diabetes in muscle, kidney, and perhaps other organs.
In our study, delivery of the miR-23a∼27a∼24-2 precursor
RNA by AAV produces both miR-23a and miR-27a, both of
which target mRNAs that encode proteins which are relevant
to the atrophy and fibrosis processes. miR-23 targets
TRIM63/MuRF1 and FBXO32/atrogin-1, PTEN, caspase-7,
SMAD3, and RAS GTPase-activating protein SH3 domain-
binding protein 2 (G3BP2), whereas miR-27 targets FoxO1,
SMAD2, SMAD4, and myostatin.18,20,34–36 We found that
miR-23a is lower in diabetic skeletal muscle, compared with
controls. The decrease in miR-23a contributes to the well-
documented increase in expression of TRIM63/MuRF1 and
FBXO32/atrogin-1 E3 ubiquitin ligases as well as dysfunc-
tional insulin signalling (i.e., increased PTEN and decreased
Akt phosphorylation).18 Furthermore, the decline in miR-23a
contributes to the observed increase in SMAD3 seen in dia-
betic muscle, a finding consistent with other reports that
miR-23a targets SMAD3 in chondrocytes.36 This finding is no-
table because Zhang et al. found that increased SMAD2/3 sig-
nalling leads to inhibition of Akt phosphorylation, activation of
caspase-3, and the ubiquitin-proteasome system, responses
that are linked to the muscle atrophy process.12,28 Other miRs,
such as miR-328, have been linked to Inhibits renal tubular cell
epithelial-to-mesenchymal transition in pressure-induced re-
nal fibrosis.37 However, there is no current evidence that alter-
ing the levels of miR-23/27 has an influence on pressure-
related tubular fibrosis or renal epithelial-to-mesenchymal
transition. Our finding that provision of miR-23a to the muscle
of diabetic mice via AAV-miR-23a∼27a∼24-2 reversed these
changes further supports the conclusion that a decrease in
miR-23a in muscle is a substantial contributing factor to the
loss of muscle mass during diabetes.
The mechanism(s) responsible for the reduction of miR-
23a in skeletal muscle would include increase packaging of
miR-23a/27a into exosomes. We previously reported that
Figure 5 Intramuscular injection of adeno-associated virus (AAV)-23a~27a~24-2 increased serum-derived exosome size. (A) Total RNA was isolated
from serum-derived exosomes of control plus AAV-green fluorescent protein (AAV-ctrl), control plus AAV-miR-23a/27a, diabetes (DM) plus AAV-ctrl,
and DM plus AAV-miR-23a/27a mice. The expressions of miR-23a-3p, miR-27a-3p, and miR-24-2 were assayed by real-time quantitative polymerase
chain reaction. The bar graph shows miR expression from the exosomes of each group of mice compared with levels in control mice (represented
by a line at one-fold). Results are normalized to miR-103a (bars: mean ± s.e.; n = 6/group; *p < 0.05 vs. diabetes and #p < 0.05 vs. control). (B) Total
RNA was isolated from whole kidney of different groups of mice. The expressions of miR-23a-3p, miR-27a-3p, and miR-24-2 were assayed by real-time
quantitative polymerase chain reaction. The bar graph shows miR expression from the exosomes of each group of mice compared with levels in control
mice (represented by a line at one-fold). Results are normalized to U6 (bars: mean ± s.e.; n = 6/group; *p< 0.05 vs. diabetes and #p< 0.05 vs. control).
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Figure 6 Evidence of muscle-kidney cross talk. (A) The green fluorescent protein (GFP) distribution was determined in different organs 2 weeks after
intramuscular injection of adeno-associated virus (AAV)-GFP in normal mice. Each organ was removed from the mice that received intramuscular in-
jection of AAV-GFP only in the left tibialis anterior (TA) muscle (top) and those that did not receive any injection (non-injection) control (bottom) and
the images acquired by using a Bruker small animal optical imaging system (in-vivo Xtreme II). The bar graph shows GFP intensity from the each organ
of the AAV-GFP-injected mice compared with levels in organs from the non-injected control mice (represented by a line at one-fold) (bars: mean ± s.e.;
n = 3/group;
*
p < 0.05 vs. non-injected controls). (B) The intensity of muscle GFP was correlated with the intensity of kidney GFP after intramuscular
injection of different titres of AAV-GFP (from 107 to 1012) into TA muscles of normal mice. The images were taken 1 week after injection by using the
in-vivo Xtreme camera system. The increase of muscle GFP intensity and the increase of kidney GFP intensity were examined by linear regression
(r = 0.596; p < 0.001). Each point represents one animal (n = 17). (C) The GFP protein was measured by western blotting in kidney and muscle lysates
from intramuscular AAV-GFP-injected normal mice at different times after injection. The muscle and kidney from GFP-positive mice (C57BL/6J-nnnnn
(CAG-EGFP)10sb/J) were used as the positive control. The bar graph shows the fold change of the GFP protein band (normalized to GAPDH) from mus-
cle (left) and kidney (right) at 3, 7, and 14 days post injection in the injected mice compared with levels in non-injected mice (day 0) (bars: mean ± s.e.;
n = 6/group; #p < 0.05 vs. control). (D) The DNA was isolated from muscle and kidney from intramuscular injection of AAV-GFP in normal mice and
assayed for AAV-virus inverted terminal repeat (ITR) by quantitative polymerase chain reaction. The level of the AAV-ITR gene was used to identify
the presence of virus. The bar graph compares the ITR levels in muscle, serum exosomes, and kidney, expressed as a fold change from levels compa-
rable samples from non-injected control mice. Results are normalized to glyceraldehyde 3-phosphate dehydrogenase DNA (bars: mean ± s.e.; n = 6 and
#
p < 0.05 vs. controls).
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miRs, including miR-23a, are selectively packaged into
exosomes which are released from cultured myotubes.19,38
Our findings of increased miR-23a and miR-27a in exosomes
and kidney following injection of AAV-miR-23a∼27a∼24-2
into the TA muscle further support a model in which miRs
are released into the circulation in exosomes (and perhaps
other microvesicles) from muscle. Our data also indicate that
circulating exosomes containing miR-23a/27a are taken up by
various organs including kidney. Exosomes are ideal vehicles
for transporting miRs because they stabilize miR and are less
immunogenic and cytotoxic than other viral or liposome-
based gene delivery vehicles.39,40 In the case of miR-23a/
27a, this leads to an increase in the levels of these miRs
and a concurrent decrease in the expression of SMAD3, its
downstream signalling, and proteins associated with fibrosis.
Studies with AAV-GFP and measurements of viral ITR support
this model. The fact that ITR-DNA is not present in exosomes
or kidney suggests that the virus does not travel to the other
organs. This is strong evidence that the increased levels of
miR-23a/27a in kidney therefore results from miR movement
from muscle to kidney, and not AAV redistribution.
Diabetic kidney disease is characterized by increased glo-
merular mesangial hypertrophy, matrix deposition, enhanced
interstitial fibrosis, etc.41 We used AAV-GFP to identify into
which parts of the kidney the muscle-derived exosomes local-
ized. The predominant localization of the GFP label was to in-
terstitial areas. While fluorescence was seen overlapping with
glomeruli, there was no specific tendency to localize to these
structures (Figure S2). Because diabetic nephropathy is
largely a glomerular disease, determining strategies to im-
prove miR delivery to glomeruli will require future study.
Our previous study found that miR-23 expression was in-
creased in skeletal muscle following resistance exercise in CKD
mice and adenovirus-mediated overexpression of miR-23 and
miR-27 ameliorated muscle atrophy.18 Some investigators re-
port that miR-23 or miR-27 is increased in skeletal and cardiac
muscle in humans and rodents after exercise.42,43 In contrast,
miR-23a is decreased in human muscle after extended bed
rest.44 One study found that miR-23 can reduce skeletal muscle
atrophy by inhibition of TRIM63/MuRF1 and FBXO32/atrogin-
1.20 However, the opposing conclusion can also been found that
miR-23 is decreased in skeletal muscle following acute endur-
ance exercise in healthy adults,45 or overexpression of miR-23
does not inhibitmuscle atrophy.46 The discordantfindings could
be due to different exercise models and experimental condi-
tions. To proceed to clinical use, there is a need to further study
the off-target impact of miR-23a/27a. Boon et al. reported that
miR-23b blocks cell cycle progression, whereas miR-27b was
shown to reduce endothelial cell repulsive signals In cultured
cells.47 Given the basic processes that could be impacted, fur-
ther in vivo studies are needed to confirm these effects in nor-
mal and disease conditions.
Although the evidence provided appears to rule out a
virus-mediated transfer of GFP, and presumably miR-23a/
27a, from muscle to kidney, this possibility cannot be totally
excluded. There are reports of intracellular transfer of viral
nucleic acid (e.g. DNA or RNA) via exosomes.48 Thus, it is pos-
sible that miR-23a∼27a∼24-2 precursor RNA, rather than ma-
ture miR-23a and miR-27a, are packaged into exosomes and
transferred to the kidney, where, following uptake, the pre-
cursor is processed in renal tissues.
An additional important observation in this study is that
the apparent uptake and expression of GFP are higher in kid-
ney than other non-muscle organs (Figure 6B). There are sev-
eral possible explanations for this phenomenon. First, the
AAV rep/cap trans-plasmid that we used is pAAV2/9, which
containing contains the replicase gene from AAV2 but the
capsid gene from AAV9. In general, the tissue tropism for
AAV-9 is lung, liver, muscle, heart, and central nervous sys-
tem. It is possible that kidney has a strong preference for
AAV-2/9, which would explain why the GFP signal is so strong
in kidney relative to the other organs. Second, the kidneys
have a very high blood flow. In humans, the kidneys receive
25% of cardiac output, which has 1.1-L/min blood go through
Figure 7 Simplified schematic showing the potential strategy for muscle-
derived miR-23a/27a to attenuate muscle atrophy and renal fibrosis. In
diabetes, the insulin/IGF-1 signalling is down-regulated. In a normally
functioning insulin/IGF-1 signalling pathway, miR-23 targets the 30-UTR
of PTEN resulting in a decrease in PTEN protein amount. The decrease
in PTEN will result in increased phosphorylation of Akt, inactivation of
FoxO, and inhibition of the pro-atrophic E3 ubiquitin ligases TRIM63/
MuRF1 and FBXO32/atrogin-1 leading to blockade of muscle atrophy. Fur-
thermore, miR-23 directly targets MuRF1 and atrogin-1. The decreased
levels of MuRF1 and atrogin-1 resulting from exogenous overexpression
of miR-23 and miR-27 in a diabetic animal therefore block diabetes-in-
duced muscle atrophy. The decrease in kidney fibrosis in diabetic animals
receiving exogenous miR-23 and miR-27a may result from the influence
of miR-27a and miR-23a on the TGFβ cascade. The TGFβ/myostatin cas-
cade is down-regulated by miR-23a and miR-27a through influences on
SMADs. MiR-23a directly inhibits SMAD3 and miR-27a directly inhibits
SMAD2, the consequence of which is decreased production of extracellu-
lar matrix and decreased renal fibrosis. In addition, miR-27a directly in-
hibits myostatin, which inhibits SMAD2 in a post-transcription manner
resulting in additional up-regulation of pAkt and prevention of diabetic
muscle atrophy.
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kidney in a 70-kg adult male (total blood volume is 5.5 L). If,
as we suggest, miR-23a/27a is carried by exosomes, there will
be a very high passage rate through the kidneys. Confirma-
tion of the mechanism responsible for the enrichment of
GFP and miR-23a/27a will require additional experiments.
In summary, increasing the levels of miR-23a andmiR-27a in
muscle via AAV-miR-23a∼27a∼24-2 ameliorated diabetes-
induced skeletal muscle atrophy by up-regulating IGF1/PI3K/
Akt signalling pathway and down-regulating myostatin cas-
cade (Figure 7). In addition, overexpression of miR-23a and
miR-27a led to increased circulation of these miRs in
exosomes, which appear to be taken up by myofibres in other
muscles as well as cells in the kidneys where they had similar
beneficial effects on the atrophy process and renal fibrosis, re-
spectively. Our findings provide evidence for the existence of a
beneficial cross-talk system between skeletal muscle and
other organs including kidneys. They also suggest that main-
taining muscle mass provides renoprotective effects as well.
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Figure S1. Shown are representative Masson’s Trichrome
staining of paraffin-sections from TA muscle from control plus
AAV-GFP, control plus AAV-miR-23a/27a, diabetes plus AAV-
GFP and diabetes plus AAV-miR-23a/27a mice. The bar graph
show collagen amount (blue color), measured by the CellSens
Dimension 1.9 with count & measure Software, from the
muscle of each group of mice as a fold change relative to con-
trols as 1-fold (Bars: mean ± s.e.; n = 6/group; * = p < 0.05 vs.
control).
Figure S2. Shown are representative frozen sections of kidney
from normal control mice that had muscles transduced with
AAV-GFP. The right panel shows fluorescence microscopy to
detect GFP expression in the kidney section; the left panel
is a bright-field microscopic image of the same field (bar:
100 um).
Figure S3. Exosomes were isolated from the serum of control
mouse. The exosome size and concentration was measured
by NanoSigth Instruments. The bar graphs show size (nano-
meter diameter) of exosomes from serum of 3 of mice (Bars:
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